April 26th 2012
04/12
The pharmaceutical service provider achieved total sales of 44.6 million Swiss francs in the relocation year 2011.This constitutes a 15% decline on the previous year, mainly caused by the combination of the strong Swiss franc, weak economic activity and the impact of the relocation to the new headquarters. These factors did not affect important core services, which recorded growth despite difficult market conditions.
March 14th 2012
03/12
The Swiss Chemical Society has awarded the “Sandmeyer Award 2012 – sponsored by KPMG” to a research team from Solvias. Working for Sanofi Pasteur, the team developed an innovative, efficient and fully synthetic process for protoporphyrin IX, a precursor of hemoglobin.
January 31st 2012
01/12
This issue presents interesting topics like:
•New partnership for integrated chemical development and manufacturing services
•Leveraging the power of cocrystals
•Characterization of biologics - the deamidation of asparagine
•Accelerating chemical (process) development with HTS technology
November 07th 2011
11/11
The jury of the annual Solvias Ligand Contest awarded the 2011 prize to Dr. Syuzanna R. Harutyunyan, Assistant Professor in Synthetic Organic Chemistry at the University of Groningen. The Award Ceremony and presentation of the prize-winning contribution took place during the 10th Science Day.
November 02nd 2011
11/11
The award which was received in the category “Most Improved Process/Plant Facility”, recognized Solvias’ work for Vitae Pharmaceuticals, a clinical stage biopharmaceutical company. The award winning project provided a fully integrated approach to pharmaceutical product development.
October 31st 2011
10/11
Solvias was announced as the winner of the Exhibitor Sustainability Award at the CPhl Worldwide, ICSE, InnoPack & P-MEC Europe 2011 Exhibitor Party & Innovation Awards Ceremony on October 25th.
October 10th 2011
10/11
The Art of Crystallization Development - From Form Screening to a Stable Crystallization Process.
October 04th 2011
10/11
Solvias and RohnerChem bundle their combined strengths and complementary services to offer customers a seamless solution for fine chemicals and API development from route scouting to commercial production. The focus of this strategic partnership is to reduce commercialization timelines and to realize overall cost savings for customers.
September 08th 2011
09/11
The science and technology service company hosts its 10th annual Solvias Science Day with a inspiring program of high scientific standing. The event takes place on November 3rd, 2011 at the Congress Centre Basel, Switzerland
April 28th 2011
04/11
The new Solvias site in Kaiseraugst was inspected by the US Food and Drug Administration (FDA) on April 7th and 8th.
April 15th 2011
04/11
Timo Rager and Rolf Hilfiker's scientific paper with the title Cocrystal Formation from Solvent Mixtures made it on the top 20 list. We congratulate to this success and keep our fingers crossed.
April 14th 2011
04/11
The pharmaceutical service provider Solvias achieved total sales of CHF 52.7 million in 2010, a decline
of 13% year-on-year. Also during the year, Solvias moved to its new location in Kaiseraugst, which
serves as a symbol of the firm`s forward-looking strategy.
January 14th 2011
01/11
On February 2, 2011, Solvias' new office and laboratory building is officially opened. The company, which provides scientific and technical services, has already moved into the new building.
October 26th 2010
10/10
In recognition of her contributions in the area of asymmetric catalysis and the application of Solvias ligands, Solvias awarded the 2010 prize to Professor Jaesook Yun from the Department of Chemistry, Sungkyunkwan University, Korea.
September 20th 2010
09/10
Solvias has implemented enzyme screening and classical resolution capabilities to its screening platform as part of its chemical development service.
August 04th 2010
08/10
Solvias has been newly authorized by Swiss Authorities (Swissmedic) to manufacture and handle narcotic and psychotropic substances (APIs) at its chemical development and manufacturing sites. This represents an extension to the existing license to handle controlled substances in its analytical division.
July 06th 2010
07/10
With the upcoming event, the science and technology service company will be adding extra strings to its bow far beyond chemical development and catalysis and will for the first time be offering a series of lectures on solid-state development and on the analysis of small and large molecules. In addition to contributions from science, case studies from industry will ensure that there is a particularly practical element.
May 25th 2010
05/10
Solvias AG announces agreement for the manufacturing of the active pharmaceutical ingredient (API) for Rottapharm|Madaus’s phase I candidate, CR4056. Solvias will provide ongoing process R&D support and deliver the CR4056 API, produced in its GMP-approved API manufacturing facility, for use in planned Phase 1 clinical studies.
May 05th 2010
05/10
Following five years of very successful growth, sales developments have now been slowed by the global crisis in the financial markets and the changes in the economic situation in general.
March 05th 2010
03/10
Dr. Hans-Ulrich Blaser has been selected to receive the Rylander Award from the Organic Reactions Catalysis Society (ORCS) at the 23rd Conference on Catalysis of Organic Reactions March 14-18, 2010.
February 08th 2010
02/10
Solvias AG and Vitae Pharmaceuticals announced today the companies have entered into an agreement for the manufacturing of the active pharmaceutical ingredient (API) for Vitae’s lead product candidate, VTP-27999. Solvias will provide ongoing process R&D support and deliver the VTP-27999 API, produced in its new GMP-approved API manufacturing facility, for use in planned Phase 2 clinical studies.
January 21st 2010
01/10
Construction work on the new Solvias AG headquarters in Römergarten, Kaiseraugst, is moving full speed ahead. The actual framework of the building was already completed in late November, while the traditional topping off ceremony was held on January 20, 2010.
November 02nd 2009
11/09
F. Dean Toste and Nicolai Cramer share first prize of the Solvias Ligand Contest
October 19th 2009
10/09
The award was received in the category “Best Analytical Contract Project”.
October 15th 2009
10/09
Solvias earned the award for its innovative effords to prevent and reduce environmental impacts of its exhibiton stand
October 12th 2009
10/09
Solvias AG and SARcode Corporation have entered into an expanded agreement for the chemical development and manufacturing of SARcode›s active pharmaceutical ingredient (API) SAR 1118. Solvias will provide ongoing process R&D support and deliver SAR 1118 for use in phase II clinical studies in its new GMP API manufacturing facility.
September 21st 2009
09/09
Solvias AG was founded as an independent spin-off on October 1, 1999. Throughout the last decade, Solvias has extended its market activities from the Basel region to other parts of Europe and America. Since its inception, Solvias has been a service provider for analytical and chemical development.
September 01st 2009
09/09
Solvias complements its services with a new GMP kilo laboratory. The first custom manufacturing campaign for an active pharmaceutical ingredient (API) will start this month.
August 26th 2009
08/09
Solvias delivered more than 200 kg of a key component, meeting Rolic’s very high quality expectations for application in their photo alignment technology.
May 07th 2009
05/09
The scientific and technical services company is constructing a five-story building with room for more than 300 state-of-the-art laboratory and office workspaces in Römergarten. The ceremonial laying of the foundation stone took place on May 7 in Römergarten.
April 28th 2009
04/09
Technology provider Solvias and catalyst manufacturing company Umicore have entered a long term cooperation allowing quid pro quo access to each company’s respective asymmetric catalysis technologies. Through this collaboration, chiral ligands and chiral metal complexes are made available at industrial scale.
April 27th 2009
04/09
At their annual general meeting, the shareholders of the pharmaceutical service provider Solvias approved all the motions put forward by the board of directors (BoD). The new president of the board of directors is Luzi von Bidder.
April 14th 2009
04/09
The pharmaceutical service provider Solvias has shown growth again in 2008. The divisions of Analytical Services and Process Analytical Technology especially contributed to this growth. “Through investment in the future, we keep to our long-term plan for growth,” says Hansjörg Walther, CEO Solvias.
February 25th 2009
02/09
On the occasion of the chemistry lecturers conference of the GDCh in Göttingen, Hans-Ulrich Blaser Chief Technology Officer at Solvias AG, will receive the Horst Pracejus Prize on 9th March 2009 “in recognition of his ground breaking and essential work, with which it was possible to use homogeneous and heterogeneous asymmetrical catalytic procedures in the industry".
January 20th 2009
01/09
It has begun. With the groundbreaking ceremony, the building works for the new headquarters of Solvias AG in Kaiseraugst have commenced.
December 02nd 2008
12/08
The jury of the annual Solvias Ligand Contestawarded the 2008 prize to Professor Walter Baratta on November 18 at the Congress Center in Basel. Professor Baratta, of the Dipartimento di Scienze e Tecnologie Chimiche, Università di Udine (Italy), has
November 13th 2008
11/08
Patheon (TSX:PTI), and Solvias AG, are pleased to announce a global alliance to offer integrated development services to pharmaceutical and biotechnology companies. This alliance combines Patheon’s experience and expertise in formulation development
October 28th 2008
10/08
Solvias has announced the construction of its new kg-scale cGMP manufacturing plant in Basel, which is planned to be operational within Q2/09. The facility will complement the existing state-of-the-art kilo lab by rapid and cost-effective manufacturi
September 29th 2008
09/08
Solvias AG, Basel (Switzerland) has acquired an exclusive license from Evonik Degussa GmbH, Essen (Germany) to develop, manufacture, and market the catASium® and cataCXium® ligand product lines. The new license will enhance the status of Solvias as o
March 24th 2008
03/08
2007 was a record year for Basel-based Solvias AG, which increased its sales by 20%. Total revenue including licensing increased by CHF 10.5 million to CHF 63.5 million. Sales from international business topped those in Switzerland for the first time
February 05th 2008
02/08
The Board of Directors of Solvias AG in Basel has decided to build a new headquarters in Kaiseraugst. The preliminary contract to buy the land was signed at the start of January 2008, with construction work due to start in a few months’ time.
May 08th 2007
05/07
Prof. Armido Studer (Münster, Germany) convincingly won the 2007 contest with his significant contribution to the field of homogeneous catalysis using Solvias ligands.
March 22nd 2007
03/07
Strong demand for our products and services in 2006 coupled with a sustained increase in capacity utilization led to a 9% rise in sales over the previous year. The American market recorded the largest sales growth, with a double-digit percentage incr
July 05th 2006
07/06
Solvias has licensed the rights to manufacture, market, and distribute the well-known MeOBIPHEP catalyst technology from Roche.
May 08th 2006
05/06
2006, the jury has awarded the first prize jointly to two winners. Prof. Ken Tanaka (Tokyo, Japan) and Prof. Michael J. Krische (Austin, Texas, USA) are honored in recognition of their significant contributions in the area of asymmetric catalysis and
March 29th 2006
03/06
Sales growth in Europe and North America, as well as disproportionate growth in licensing revenue, led to an increase in total revenues of around 10% to 52 million Swiss francs. Along with the rise in demand for services and products there was a mark
February 14th 2006
02/06
Solvias has exclusively licensed a highly efficient CN-coupling technology for aromatic and heteroaromatic chlorides, bromides and sulfonates with amines and imines from Yale University (US patents 5,977,361 and 6,235,938 B1). The licensing of this CN-coupling
February 14th 2006
02/06
Solvias launches its first full-scale High-Throughput Catalysis Screening Service for asymmetric homogeneous hydrogenation. The fully automated system utilizes standard 96-well plates combined with analysis by supercritical fluid chromatography (SFC)
March 22nd 2005
03/05
With a 14% increase in 2004 total revenue, Solvias is back on track for growth. Sales grew by 6% in Switzerland, were as an overproportional increase was also recorded in the European markets. In the United States sales also outperformed expectations
January 17th 2005
01/05
Solvias AG announced 2005 the execution of a research and development agreement with Pfizer Inc., Global Research and Development. This agreement will allow Pfizer to access Solvias’s chiral ligand and asymmetric catalysis technology for the process
October 07th 2004
10/04
New alliance enhances BASF’s technology platform for optically active intermediates. BASF has signed a cooperation agreement with Solvias AG, Basel, Switzerland. In cooperation with Solvias, BASF will use these ligands to manufacture optically active
